SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Gillian P. Bates, Ray Dorsey, James F. Gusella, Michael R. Hayden, Chris Kay, Blair R. Leavitt, Martha Nance, Christopher A. Ross, Rachael I. Scahill, Ronald Wetzel, Edward J. Wild, Sarah J. Tabrizi, Huntington disease, Nature Reviews Disease Primers, 2015, 15005

    CrossRef

  2. 2
    Ruth H. Walker, Movement Disorders, 2015,

    CrossRef

  3. 3
    Barbara J. Zarowitz, Terrence O'Shea, Martha Nance, Clinical, Demographic, and Pharmacologic Features of Nursing Home Residents With Huntington's Disease, Journal of the American Medical Directors Association, 2014, 15, 6, 423

    CrossRef

  4. 4
    Christopher A. Ross, Alex Pantelyat, Jane Kogan, Jason Brandt, Determinants of functional disability in Huntington's disease: Role of cognitive and motor dysfunction, Movement Disorders, 2014, 29, 11
  5. 5
    N Ahmad Aziz, Raymund AC Roos, Characteristics, pathophysiology and clinical management of weight loss in Huntington’s disease, Neurodegenerative Disease Management, 2013, 3, 3, 253

    CrossRef

  6. 6
    Cristiani F. Bortolatto, Cristiano R. Jesse, Ethel A. Wilhelm, Pietro M. Chagas, Cristina W. Nogueira, Organoselenium Bis Selenide Attenuates 3-Nitropropionic Acid-Induced Neurotoxicity in Rats, Neurotoxicity Research, 2013, 23, 3, 214

    CrossRef

  7. 7
    C.M. Eddy, H.E. Rickards, Moral judgment and decision making in Huntington’s disease, Basal Ganglia, 2012, 2, 3, 139

    CrossRef

  8. 8
    Martha A. Nance, Therapy in Huntington’s Disease: Where Are We?, Current Neurology and Neuroscience Reports, 2012, 12, 4, 359

    CrossRef

  9. 9
    Raphael M. Bonelli, M. Flint Beal, Neurobiology of Psychiatric Disorders, 2012,

    CrossRef

  10. 10
    Textbook of Clinical Neuropsychiatry and Behavioral Neuroscience 3E, 2012,

    CrossRef

  11. 11
    Emma Power, Alison Anderson, Leanne Togher, Applying the WHO ICF framework to communication assessment and goal setting in Huntington's Disease: A case discussion, Journal of Communication Disorders, 2011, 44, 3, 261

    CrossRef

  12. 12
    Adam Rosenblatt, Brahma V. Kumar, Russell L. Margolis, Claire S. Welsh, Christopher A. Ross, Factors contributing to institutionalization in patients with Huntington's disease, Movement Disorders, 2011, 26, 9
  13. 13
    Jorien M.M. van der Burg, Annika Winqvist, N. Ahmad Aziz, Marion L.C. Maat-Schieman, Raymund A.C. Roos, Gillian P. Bates, Patrik Brundin, Maria Björkqvist, Nils Wierup, Gastrointestinal dysfunction contributes to weight loss in Huntington's disease mice, Neurobiology of Disease, 2011, 44, 1, 1

    CrossRef

  14. 14
    Sean Marks, Serena Hung, Drew A. Rosielle, Palliative Care for Patients with Huntington's Disease #201, Journal of Palliative Medicine, 2011, 14, 5, 655

    CrossRef

  15. 15
    Karen E. Anderson, Hyperkinetic Movement Disorders, 2011,

    CrossRef

  16. 16
    Kathleen M. Shannon, Hyperkinetic Movement Disorders, 2011,

    CrossRef

  17. 17
    N. A. Aziz, G. V. Anguelova, J. Marinus, J. G. Van Dijk, R. A. C. Roos, Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington’s disease, European Journal of Neurology, 2010, 17, 8
  18. 18
    Emily Oster, Ira Shoulson, Kimberly Quaid, E. Ray Dorsey, Genetic adverse selection: Evidence from long-term care insurance and Huntington disease, Journal of Public Economics, 2010, 94, 11-12, 1041

    CrossRef

  19. 19
    N. Ahmad Aziz, Hanno Pijl, Marijke Frölich, A.W. Maurits van der Graaf, Ferdinand Roelfsema, Raymund A.C. Roos, Leptin secretion rate increases with higher CAG repeat number in Huntington’s disease patients, Clinical Endocrinology, 2010, 73, 2
  20. 20
    M.-C. Chiang, C.-M. Chen, M.-R. Lee, H.-W. Chen, H.-M. Chen, Y.-S. Wu, C.-H. Hung, J.-J. Kang, C.-P. Chang, C. Chang, Y.-R. Wu, Y.-S. Tsai, Y. Chern, Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma, Human Molecular Genetics, 2010, 19, 20, 4043

    CrossRef

  21. 21
    Nigel I. Wood, Anna O.G. Goodman, Jorien M.M. van der Burg, Véronique Gazeau, Patrik Brundin, Maria Björkqvist, Åsa Petersén, Sarah J. Tabrizi, Roger A. Barker, A. Jennifer Morton, Increased thirst and drinking in Huntington's disease and the R6/2 mouse, Brain Research Bulletin, 2008, 76, 1-2, 70

    CrossRef

  22. 22
    N.A. Aziz, Hypothalamic Dysfunction and Neuroendocrine and Metabolic Alterations in Huntington Disease: Clinical Consequences and Therapeutic Implications, Reviews in the Neurosciences, 2007, 18, 3-4

    CrossRef

  23. 23
    Karen E. Anderson, Huntington's Disease and Related Disorders, Psychiatric Clinics of North America, 2005, 28, 1, 275

    CrossRef

  24. 24
    Araceli Trejo, Marie-Catherine Boll, Ma. Elisa Alonso, Adriana Ochoa, Leora Velásquez, Use of oral nutritional supplements in patients with Huntington’s disease, Nutrition, 2005, 21, 9, 889

    CrossRef

  25. 25
    Raphael M Bonelli, Peter Hofmann, A review of the treatment options for Huntington’s disease, Expert Opinion on Pharmacotherapy, 2004, 5, 4, 767

    CrossRef

  26. 26
    Araceli Trejo, Rosa Marı́a Tarrats, Ma.Elisa Alonso, Marie-Catherine Boll, Adriana Ochoa, Leora Velásquez, Assessment of the nutrition status of patients with Huntington's disease, Nutrition, 2004, 20, 2, 192

    CrossRef

  27. 27
    Karen E. Anderson, Karen S. Marder, An overview of psychiatric symptoms in Huntington’s disease, Current Psychiatry Reports, 2001, 3, 5, 379

    CrossRef

  28. 28
    Carol Brown Moskowitz, Karen Marder, Palliative care for people with late-stage huntington's disease, Neurologic Clinics, 2001, 19, 4, 849

    CrossRef

  29. 29
    Martha A. Nance, Clinical Aspects of CAG Repeat Diseases, Brain Pathology, 1997, 7, 3